Newsletter Signup - Under Article / In Page"*" indicates required fields Many respiratory diseases have a huge effect on the lungs and other parts of the respiratory system and can be caused by various factors, including infection, exposure to air pollution, or smoking tobacco. This therapeutic area is very broad and there are numerous companies working on developing innovative therapies for different types of respiratory diseases, with cystic fibrosis and idiopathic pulmonary fibrosis being among the most popular indications for biotechs. In this article, we take a look at eight respiratory disease companies advancing novel therapies in 2025. Arrowhead Pharmaceuticals Technology: RNAi  Respiratory disease candidates: ARO-RAGE and ARO-MMP7Recent news: Collaboration with Sarepta Therapeutics that includes ARO-MMP7Equipped with a targeted RNAi molecule platform that leverages a natural pathway to “silence” genes causing disease, Arrowhead Pharmaceuticals has several focus areas, one of which is pulmonary diseases. The company has two clinical candidates in development related to respiratory diseases – one for inflammatory pulmonary diseases and one for idiopathic pulmonary fibrosis. The inflammatory pulmonary disease candidate is called ARO-RAGE. It is an RNAi therapeutic targeting the receptor for advanced glycation end-products (RAGE), which is implicated as an upstream mediator of type 2 and non-type 2 inflammatory cascades and is involved in the pathogenesis of asthma and numerous inflammatory diseases. The therapy is currently being investigated in a phase 1/2 study for the treatment of asthma

The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their gene editing collaboration with Intellia

Recode Therapeutics has secured $15 million in funding, led by The Cystic Fibrosis Foundation. The investment will be used to develop a gene editing therapy aimed at delivering treatment to the lung cells of individuals with cystic fibrosis.